KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EPS (Weighted Average and Diluted) (2010 - 2026)

Rigel Pharmaceuticals' quarterly EPS (Weighted Average and Diluted) came in at $0.44 in Q1 2026, down 30.16% year-on-year from $0.63 in Q1 2025, and down 96.88% quarter-over-quarter from $14.1 in Q4 2025.

Rigel Pharmaceuticals has reported EPS (Weighted Average and Diluted) for 11 years, with the latest figure at $0.44 in Q1 2026.

  • For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 30.16% year-over-year to $0.44; the trailing twelve-month figure through Mar 2026 stood at $19.28 (up 826.92% YoY), and the FY2025 full-year result was $19.48, up 1867.68% from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 stood at $0.44, down from $14.1 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $14.1 in Q4 2025, with the low at -$3.09 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.98, with a median of -$0.06 recorded in 2024.
  • Year-over-year, EPS (Weighted Average and Diluted) plunged 2107.14% in 2022 and jumped 5566.67% in 2025.
  • Tracing RIGL's EPS (Weighted Average and Diluted) over 5 years: stood at -$3.09 in 2022, then jumped by 101.62% to $0.05 in 2023, then soared by 1520.0% to $0.81 in 2024, then soared by 1640.74% to $14.1 in 2025, then tumbled by 96.88% to $0.44 in 2026.
  • The last three EPS (Weighted Average and Diluted) figures came in at $0.44 (Q1 2026), $14.1 (Q4 2025), and $1.46 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -4.43
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 3,086.42
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 0.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 4.02
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 6.75
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.51
10 Rigel Pharmaceuticals 551.62 Mn 404.94 Mn 54.21 Mn 0.44

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.44
Dec 31, 2025 14.10
Sep 30, 2025 1.46
Jun 30, 2025 3.28
Mar 31, 2025 0.63
Dec 31, 2024 0.81
Sep 30, 2024 0.70
Jun 30, 2024 -0.06
Mar 31, 2024 -0.47
Dec 31, 2023 0.05
Sep 30, 2023 -0.33
Jun 30, 2023 -0.38
Mar 31, 2023 -0.08
Dec 31, 2022 -3.09
Sep 30, 2022 -0.11
Jun 30, 2022 -0.08
Mar 31, 2022 -0.16
Dec 31, 2021 -0.14
Sep 30, 2021 -0.12
Jun 30, 2021 -0.08
Mar 31, 2021 0.22
Dec 31, 2020 -0.12
Sep 30, 2020 -0.08
Jun 30, 2020 -0.10
Mar 31, 2020 0.13
Dec 31, 2019 -0.10
Jun 30, 2019 -0.12
Mar 31, 2019 -0.11
Dec 31, 2012 -0.29
Sep 30, 2012 -0.36
Jun 30, 2012 -0.35
Mar 31, 2012 -0.32
Dec 31, 2011 -0.37
Sep 30, 2011 -0.25
Jun 30, 2011 -0.37
Mar 31, 2011 -0.40
Dec 31, 2010 -0.33
Sep 30, 2010 0.96
Jun 30, 2010 0.51